Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Emergent Biosolutions
(NY:
EBS
)
4.350
-0.020 (-0.46%)
Official Closing Price
Updated: 7:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Emergent Biosolutions
< Previous
1
2
3
4
5
6
7
8
9
Next >
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
June 29, 2021
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-...
Via
Benzinga
Exposures
COVID-19
A Look Into Healthcare Sector Value Stocks
June 28, 2021
What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be...
Via
Benzinga
5 Value Stocks To Watch In The Healthcare Sector
June 21, 2021
A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT
June 11, 2021
The FDA has asked Johnson & Johnson (NYSE: JNJ) to discard 60 million doses of its COVID-19 vaccine manufactured at the troubled Emergent BioSolutions Inc...
Via
Benzinga
Exposures
COVID-19
Product Safety
AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT
June 03, 2021
AstraZeneca Plc (NASDAQ: AZN) is in talks with the U.S. government to shift production of its COVID-19 vaccine from a troubled Emergent BioSolutions Inc’s (...
Via
Benzinga
Exposures
COVID-19
Emergent BioSolutions Poised To Receive FDA Nod to Restart J&J COVID-19 Shot Production at Baltimore Plant After Mishap: WSJ
May 28, 2021
The FDA and Johnson & Johnson (NYSE: JNJ) are expected to announce that contamination problems at Emergent BioSolutions Inc’s (NYSE: EBS) Baltimore...
Via
Benzinga
Exposures
COVID-19
Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 28, 2021
Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 21.13% to $1.49 during Friday's pre-market session. The company's market cap stands at $266.9...
Via
Benzinga
Justice Department Opens Probe In Presumed lapses at Eli Lilly's COVID-19 Drug Plant: Reuters
May 27, 2021
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (NYSE: LLY) focused on alleged manufacturing irregularities and records...
Via
Benzinga
Exposures
COVID-19
Emergent BioSolutions's Single-Dose Chikungunya Vaccine Candidate Effective Even After Two Years of Vaccination
May 26, 2021
Emergent BioSolutions Inc (NYSE: EBS) has announced two-year persistence data from its Phase 2 study evaluating its investigational chikungunya virus, virus-like...
Via
Benzinga
Emergent BioSolutions Stock Falls As Executives Face Questions As Part Of Botched Vaccine Probe
May 19, 2021
The House Select Subcommittee on the Coronavirus announced last month that they were opening an investigation into Emergent BioSolutions Inc (NYSE: EBS), with...
Via
Benzinga
Exposures
COVID-19
Cramer Weighs In On Beyond Meat, Snowflake, More
May 18, 2021
Jim Cramer said on CNBC's "Mad Money Lightning Round" he would buy more shares of Anthem Inc (NYSE: ANTM). He also likes UnitedHealth Group Inc (NYSE: UNH) and...
Via
Benzinga
Emergent Initiates Quality Enhancement Plan For Troubled Baltimore Vaccine Facility
May 12, 2021
Emergent BioSolutions Inc (NYSE: EBS) has been in headlines after its Baltimore plant has drawn the scrutiny of the FDA. A manufacturing mix-up ruined 15 million...
Via
Benzinga
Exposures
Product Safety
FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic
May 10, 2021
The FDA has published a roadmap for working through the backlog of facility inspections built up during the pandemic when it postponed all routine inspections in March...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
May 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
May 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021
May 05, 2021
Upgrades Atlantic Equities upgraded the previous rating for Under Armour Inc (NYSE:UAA) from Underweight to Neutral. Under Armour earned $0.16 in the first quarter. The...
Via
Benzinga
Why Emergent BioSolutions Stock Dropped 30% in April
May 04, 2021
The company went from hero to zero in the fight against COVID-19.
Via
The Motley Fool
Exposures
COVID-19
Is Emergent BioSolutions Still a Buy After Its Coronavirus Vaccine Flub?
May 04, 2021
Shareholders beware: The hits just won't stop coming.
Via
The Motley Fool
Exposures
COVID-19
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
April 30, 2021
Emergent BioSolutions Inc has manufactured over 115 million doses of the drug substance used in the Johnson & Johnson COVID-19 vaccine, 60 million doses of which are in vials and ready to deploy at...
Via
Talk Markets
Exposures
COVID-19
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues
May 05, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg
April 30, 2021
Emergent BioSolutions Inc (NYSE: EBS) has manufactured over 115 million doses of drug substance used in the Johnson & Johnson (NYSE: JNJ) COVID-19...
Via
Benzinga
Exposures
COVID-19
Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days
April 30, 2021
Emergent BioSolutions Inc (NYSE: EBS) said it hopes to respond to U.S. regulators within days on how to resolve the problems at its Baltimore plant, which have forced...
Via
Benzinga
Exposures
Product Safety
Emergent BioSolutions Inc (EBS) Q1 2021 Earnings Call Transcript
April 30, 2021
EBS earnings call for the period ending March 31, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Emergent BioSolutions: Q1 Earnings Insights
April 29, 2021
Shares of Emergent BioSolutions (NYSE:EBS) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15200.00% over the...
Via
Benzinga
A Preview Of Emergent BioSolutions's Earnings
April 28, 2021
Emergent BioSolutions (NYSE:EBS) announces its next round of earnings this Thursday, April 29. Here is Benzinga's everything-that-matters guide for this Thursday's Q1 earnings...
Via
Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
April 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
Is There Any Hope Left for Emergent BioSolutions?
April 27, 2021
The go-to government contractor is in deep trouble. Should investors buy the dip?
Via
The Motley Fool
Exposures
COVID-19
JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ
April 23, 2021
The U.S. is expected to announce its decision on Johnson & Johnson’s (NYSE: JNJ) single-shot COVID-19 vaccine on whether it should be back in circulation...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
April 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.